RECRUITING

Corneal Crosslinking for Treatment of Corneal Neovascularization

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Official Title

Randomized Comparison of Standard vs. Accelerated Corneal Crosslinking for Treatment of Corneal Neovascularization With or Without Concomitant Inflammation and/or Infection

Quick Facts

Study Start:2021-05-03

Study Completion:2025-09-15

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04787471

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* 18 years of age or older * With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids. * Signed written informed consent.	* Known sensitivity to treatment medications * Current condition that in the investigator's opinion could compromise safety or data integrity. * Pregnancy (including plan to become pregnant) or lactation during the course of the study

Inclusion Criteria

Exclusion Criteria

* 18 years of age or older
* With active inflammation or infection causing vascularization and possibly melting of the cornea, or vessels extending into the cornea causing lipid deposition, or vascularization that could significantly increase the risk of rejection of a current or planned corneal transplant, or vessels that continue to extend into the cornea despite topical treatment with corticosteroids.
* Signed written informed consent.

* Known sensitivity to treatment medications
* Current condition that in the investigator's opinion could compromise safety or data integrity.
* Pregnancy (including plan to become pregnant) or lactation during the course of the study

Contacts and Locations

Study Contact

Marianne Price, PhD

CONTACT

317-814-2990

mprice@cornea.org

Principal Investigator

Francis W Price, Jr., MD

PRINCIPAL_INVESTIGATOR

Price Vision Group

Study Locations (Sites)

Price Vision Group

Indianapolis, Indiana, 46260

United States

Collaborators and Investigators

Sponsor: Price Vision Group

Francis W Price, Jr., MD, PRINCIPAL_INVESTIGATOR, Price Vision Group

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-05-03

Study Completion Date2025-09-15

Study Record Updates

Study Start Date2021-05-03

Study Completion Date2025-09-15

Terms related to this study

Additional Relevant MeSH Terms

Corneal Neovascularization